Jeremy Bastid

1 October 2020

Meet us at BIO-Europe 2020, October 26-29

Jeremy Bastid, CEO of OREGA Biotech, will participate in the upcoming BIO-Europe conference to be held virtuallly on october 26-29, 2020. BIO-Europe is Europe’s largest partnering conference serving the global biotech industry. Jeremy will actively take part in this business event, registered under the name of the holding company, initiative OCTALFA.    
1 July 2020

Jeremy Bastid nominated as Chief Executive Officer

Orega Biotech announces the nomination of Jeremy Bastid as Chief Executive Officer (Directeur Général) effective as of July 1st, 2020. “I have worked with Jeremy since the inception of OREGA Biotech” commented Gilles Alberici, President of Octalfa and Chairman of OREGA Biotech. “He has played a prominent role in the development of the company, both on the R&D and the business aspects. No doubt that his promotion as CEO of OREGA Biotech will help the company to further grow”, he added. “I am honored to be appointed new CEO and look forward to leading OREGA Biotech with the support from our Board”, commented Jeremy Bastid. “I am thrilled to lead this remarkable team and I am grateful for our Board’s confidence”.
5 May 2020

Role of IL-17B in cancer reviewed in Frontiers in Immunology

We review the current understanding on the IL-17B/IL-17RB expression patterns and biological activities in cancer and highlight issues that remain to be addressed to better characterize IL-17B and its receptor as potential targets for enhancing the effectiveness of the existing cancer therapies. The emerging role of the IL-17B/IL-17RB pathway in cancer, published in  Frontiers in Immunology and co-authoring Jeremy Bastid, Cécile Dejou, Aurélie Docquier and Nathalie Bonnefoy (OREGA Biotech). The review article is accessible here.    
Role of IL-17B in cancer reviewed in Frontiers in Immunology
This website uses cookies to improve your experience. By using this website you agree to our Data Protection Policy.
Read more